Quanta CEO John Milad outlines the transitional stage where a company begins to seek large-scale funding for the first time, and debates market valuations.

Juno Capital partner Edward Rudd believes that investing in medtech offers not only a long-term strategy for allocating capital, but an altruistic relief for investors.

Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.

Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.

In an interview with Medtech Insight, Octopus Ventures partner Pooja Sikka explained the approach Octopus takes to investments, and the key challenges the fund wants to address.

RYSE head tells Medtech Insight about his firm’s shift to investing in virtual primary care and telemedicine.

In this edition of Investor Eye, Medtech Insight spoke to Kyp Sirinakis, managing partner at Epidarex Capital, a transatlantic fund investing in emerging life science hubs in the US and UK. The firm recently launched a new UK fund, Epidarex Capital III, for innovative UK start-ups.

Sergey Young is on a mission to "extend healthy lifespans" by investing in longevity breakthroughs. Last year, the venture capitalist established a $100m fund investing in technologies with the potential to improve healthy long living.

In this edition of Investor Eye, Medtech Insight meets with Howard Rowe, managing director and head of health care at Hayfin Capital Management, a $17bn international asset management firm headquartered in London.

Israeli healthtech fund Accelmed is seizing the opportunity to implement a medtech-investment strategy that is delivering big returns. In this Medtech Insight feature, Irit Yaniv, partner at Israeli VC Accelmed, discusses changing trends in the medtech VC industry and the hot new areas of medical technology coming out of Israel.